Get the Stockscreener App
4.81
1.91%
0.09
Cingulate Inc stock is traded at $4.81, with a volume of 119.80K.
It is up +1.91% in the last 24 hours and up +8.09% over the past month.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
See More
Previous Close:
$4.72
Open:
$4.77
24h Volume:
119.80K
Relative Volume:
0.82
Market Cap:
$20.42M
Revenue:
-
Net Income/Loss:
$-21.21M
P/E Ratio:
-0.1475
EPS:
-32.6
Net Cash Flow:
$-16.86M
1W Performance:
+8.58%
1M Performance:
+8.09%
6M Performance:
+1.05%
1Y Performance:
+16.52%
1-Day Range:
$4.65
$5.00
1-Week Range:
$4.25
$5.00
52-Week Range:
$1.8001
$20.83
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.81 | 18.81M | 0 | -21.21M | -16.86M | -32.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
What makes Cingulate Inc. Equity Warrant stock attractive to long term investors200 Percent Profit Outlook - Newser
Why Cingulate Inc. stock attracts strong analyst attentionLow Risk ROI Maximization - Newser
How Cingulate Inc. stock performs during market volatilityFree Market Analysis Group - Newser
Why Cingulate Inc. Equity Warrant stock attracts strong analyst attentionQuick Profit Idea Stream - Newser
How Cingulate Inc. Equity Warrant stock performs during market volatilityFree Stock Index Interpretation - Newser
What makes Cingulate Inc. Equity Warrant stock price move sharplyShort Term Risk Controlled Alerts - Newser
What makes Cingulate Inc. stock price move sharplyFree Stock Movement Tracking - Newser
Cingulate hires chief legal officer ahead of filing for FDA approval - The Business Journals
Cingulate appoints Nilay Patel as Chief Legal Officer - TipRanks
Cingulate names Nilay Patel as chief legal officer ahead of FDA filing By Investing.com - Investing.com South Africa
Cingulate Inc. Appoints Nilay Patel as Chief Legal Officer - MarketScreener
Cingulate names Nilay Patel as chief legal officer ahead of FDA filing - Investing.com
Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application - GlobeNewswire
Cingulate Bolsters Executive Team With Key Legal Hire as ADHD Drug Heads to FDA Review - Stock Titan
Cingulate (NASDAQ:CING) Stock Price Up 3.3% – Here’s What Happened - Defense World
Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING) - TradingView
Breakthrough Once-Daily ADHD Drug Targets $22B Market: Analyst Coverage Reveals Commercial Launch Plans - Stock Titan
Cingulate Inc. (NASDAQ:CING) Sees Large Increase in Short Interest - Defense World
Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets - mx.advfn.com
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301 - mx.advfn.com
Cingulate Inc. expands equity plan following stockholder approval - Investing.com
Cingulate Inc Approves Key Proposals at Annual Meeting - TipRanks
Cingulate Inc. expands equity plan following stockholder approval By Investing.com - Investing.com India
Cingulate (NASDAQ:CING) Price Target Raised to $61.00 at Ascendiant Capital Markets - Defense World
Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer - Quantisnow
CING: Ascendiant Capital Raises Price Target to $61.00 | CING St - GuruFocus
Healthcare Tech Leader Life365 Taps Former Nasdaq CEO Jay Roberts to Drive AI-Powered Growth Strategy - Stock Titan
What is Roth Capital’s Estimate for Cingulate Q2 Earnings? - Defense World
McCann Joburg acquires a healthcare marketing company - Bizcommunity
Cingulate Reports Positive Data From Phase 3 Study Of CTx-1301 In Pediatric ADHD - Nasdaq
Cingulate announces efficacy results from Phase 3 study of CTx-1301 - TipRanks
Cingulate (CING) Reveals Promising Phase 3 Results for ADHD Treatment | CING Stock News - GuruFocus
Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD - GlobeNewswire
CING: Roth Capital Lowers Price Target, Maintains Buy Rating | CING Stock News - GuruFocus
CING: Roth Capital Adjusts Price Target Amidst CTx-1301 Developm - GuruFocus
Cingulate price target lowered to $11 from $12 at Roth Capital - TipRanks
CING: Roth Capital Adjusts Price Target Amidst CTx-1301 Developments | CING Stock News - GuruFocus
Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug - MSN
CING: First Quarter 2025 Results - Yahoo Finance
Cingulate receives FDA meeting feedback on ADHD drug By Investing.com - Investing.com Canada
Anchoring Your Portfolio: Is CING Stock a Safe Harbor? - investchronicle.com
Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug By Stocktwits - Investing.com India
Cingulate, Inc. Reports Increased Losses Amid R&D Expansion - TipRanks
Cingulate receives formal pre-NDA meeting minutes from FDA for CTx-1301 - TipRanks
Cingulate (CING) Prepares for NDA Submission for ADHD Treatment - GuruFocus
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):